Drug intelligence / Profile preview

Fendrix

Development stage: Unknown
Lead developer: Imperial College London
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Fendrix** is an AS04C-adjuvanted recombinant hepatitis B vaccine developed and manufactured by GSK. Each 0.5 mL dose contains 20 micrograms of recombinant hepatitis B surface antigen produced in *Saccharomyces cerevisiae*, adjuvanted with 3-O-desacyl-4'-monophosphoryl lipid A and aluminium phosphate. It is authorised in the European Union for active immunisation against hepatitis B virus infection in people aged 15 years and older with renal insufficiency, including pre-haemodialysis and haemodialysis patients. The vaccine induces hepatitis B surface antigen-specific immune responses and protective anti-hepatitis B surface antibodies.

Brand names: Fendrix
Other names: hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Fendrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fendrix.

Explore the full profile